A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
2020 · New England Journal of Medicine · 5,464 citations
https://doi.org/10.1056/nejmoa2001282
X
Xia Liu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
157
Papers
7.0K
Citations
19
h-index
45
i10-index
Xia Liu is an academic researcher from Shanghai University. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & Lung Cancer Treatments and Mutations. The author has an h-index of 19, co-authored 134 publications.
ORCID: 0000-0002-9768-2583Papers by this author
worksAdverse events in the nervous system associated with blinatumomab: a real-world study
2025 · BMC Medicine · 18 citations
https://doi.org/10.1186/s12916-025-03913-6
Mining and characterization of novel antimicrobial peptides from the large-scale microbiome of Shanxi aged vinegar based on metagenomics, molecular dynamics simulations and mechanism validation
2024 · Food Chemistry · 14 citations
https://doi.org/10.1016/j.foodchem.2024.140646
AGR, LMR and SIRI are the optimal combinations for risk stratification in advanced patients with non-small cell lung cancer following immune checkpoint blockers
2025 · International Immunopharmacology · 10 citations
https://doi.org/10.1016/j.intimp.2025.114215
Environmental regulation, energy poverty and social welfare: Based on China's provincial panel data
2024 · Energy Strategy Reviews · 7 citations
https://doi.org/10.1016/j.esr.2024.101592
NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy
2024 · Clinical & Translational Oncology · 4 citations
https://doi.org/10.1007/s12094-024-03735-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat